BioSphere Medical, Inc. develops, manufactures, and markets products for medical procedures that use embolotherapy. The company focuses on the treatment of symptomatic uterine fibroids, which are noncancerous, or benign, hyper vascular tumors growing within or on the wall of the uterus, using a procedure known as uterine fibroid embolization. It produces microsphere products, including Embosphere Microspheres for the treatment of symptomatic uterine fibroids, hypervascularized tumors, and arteriovenous malformations; EmboGold Microspheres for the treatment of hypervascularized tumors and arteriovenous malformations; HepaSphere Microspheres for the treatment of primary and metastatic liver cancer; and QuadraSphere Microspheres for the treatment of hypervascularized tumors and arteriovenous malformations. The companys delivery system products include EmboCath Plus Infusion Microcatheter for infusing various diagnostic, embolic, and therapeutic agents and super-selective angiography within peripheral vasculature; Sequitor Steerable Guidewire and Tenor Steerable Guidewire for use in various diagnostic and interventional procedures within peripheral vasculature; and Segway Guidewire for use in peripheral embolization procedures. It markets its embolotherapy and delivery systems products through direct sales force in the United States and France; and through distributors in Europe, Asia, Canada, the Middle East, South America, and rest of the world. The company was founded in 1993 and is based in Rockland, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for BSMD